Skip to content
Menu

Truist Securities Upgrades Edwards Lifesciences to Buy, Raises Price Target to $113

Benzinga Newsdesk 2 weeks ago

Analyst RatingsNewsUpgradesPrice TargetHot

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Truist Securities analyst Richard Newitter upgrades Edwards Lifesciences (NYSE:EW) from Hold to Buy and raises the price target from $95 to $113.

Truist Securities analyst Richard Newitter upgrades Edwards Lifesciences (NYSE:EW) from Hold to Buy and raises the price target from $95 to $113.

Read at benzinga.com